Purpose Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein.
Introduction
Paclitaxel is a highly active anticancer drug useful in the treatment of patients with, e.g., breast, lung, or ovarian cancer. It was first isolated in the 1970s from the bark of the Henrik Gréen and Troels K. Bergmann contributed equally to the work.
western yew, Taxus brevifolia [1] . In advanced ovarian cancer, the initial response rate is almost 80%, but unfortunately most patients eventually relapse [2] . Patients are allocated to treatment according to the FIGO stage (International Federation of Gynecology and Obstetrics) with post-surgery chemotherapy with a taxane and a platin being the widely accepted treatment for stages II-IV. Paclitaxel is dose-normalized to body surface area (BSA), and in most regimens infused over 1, 3, or 24 h. Dose-limiting toxicities are neutropenia and neuropathy; other toxicities include arthralgia, myalgia, and alopecia; and nausea and vomiting are experienced by less than 30% of the patients. Toxicity and clinical effects of paclitaxel differ greatly among patients and remain a clinically relevant problem with implications on survival and quality of life. Toxicity can result in dose delay, dose reduction, or even early cessation of the treatment. It has been proposed and investigated that single nucleotide polymorphisms (SNPs) could explain the variability in toxicity and effect. Sequence variants in the genome might have an impact on clinical outcome either indirectly by altering the elimination and/or disposition or directly by changes in the drug concentration in the micro environment of the cells in the different tissues.
Paclitaxel is metabolized to inactive compounds by CYP2C8 and CYP3A4 in the liver [3] [4] [5] and is also a substrate of the ATP-driven efflux pump P-glycoprotein encoded by the ABCB1 gene [6] . This study was initiated based on reports that CYP2C8*3 results in a decreased paclitaxel metabolism [7, 8] and reports of a functional significance of ABCB1 SNPs with particular interest in C1236T, G2677T/A, and C3435T [9] [10] [11] . In the study design, these four "highly implicated" and relatively frequent SNPs were selected (a priori) for the primary analysis; in addition other candidate genes linked to the pharmacodynamics and pharmacokinetics of paclitaxel were chosen for an exploratory analysis, namely CYP3A5, ABCC1, ABCC2, ABCG2, ABCC10, CYP1B1, and SLCO1B3 [12] [13] [14] [15] [16] [17] [18] . These are all drug transporters, except CYP3A5, which has a substrate range similar to CYP3A4, and CYP1B1, which has been suggested to play a role in taxane metabolism and therapeutic effects [12] .
The aim of the study was primarily to evaluate the impact of the CYP2C8*3, ABCB1 C1236T, G2677T/A, and C3435T variants on paclitaxel toxicity and survival and secondarily to explore the role of the other variants in CYP2C8 and ABCB1 as well as the variants in CYP1B1, CYP3A4/5, SLCO1B3, ABCC1, ABCC2, ABCG2, and ABCC10. We present a retrospective pharmacogenetic study of 119 Scandinavian Caucasian patients who were treated with paclitaxel and carboplatin in either the AGO-OVAR-9 trial (ClinicalTrials.gov identifier: NCT00052468) or the NSGO-OC9804 trial (NCT00004934) (phase III trials of first-line treatment of ovarian cancer).
Patients and methods

Patients
In this study, clinical data and tissue were collected from 119 patients ( Table 1) . The patients were all previously treated with paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5-6, using Calvert's formula) in either the AGO-OVAR-9 trial (OVAR-9) or the NSGO-OC9804 trial (TEC). Both trials compared a three-compound regimen to the standard treatment of paclitaxel/carboplatin in patients with primary epithelial ovarian cancer. In the OVAR-9 trial, the primary and secondary endpoints were overall survival and progression-free survival, response rate, duration of response, toxicity, and quality of life. The study closed for inclusion in April 2004. A total of 83 patients in Denmark and Sweden were randomized to paclitaxel and carboplatin. In the TEC trial, the primary and secondary endpoints were progression-free survival and overall survival, toxicity, and quality of life. The study closed for inclusion in October 2001. A total of 99 patients in Denmark and Sweden were randomized to paclitaxel and carboplatin. Treatment records and follow-up data for OVAR-9 and TEC are kept by the Eligibility criteria for this study were (1) participation in either the OVAR-9 or the TEC study in either Denmark or Sweden, (2) randomization to paclitaxel and carboplatin treatment, (3) availability of formalin-fixed, paraffinembedded tissue (any type available), and (4) availability of treatment records and follow-up data. No patients were contacted. The study was approved by the regional ethics committee of southern Denmark and the regional ethics committee in Linköping, Sweden.
Toxicity
Patients were originally evaluated for toxicity using Common Toxicity Criteria (CTC-NCIC). The two studies used revisions from March 1998 and December 1994, which have only insignificant differences regarding the chosen toxicities. Generally, grade 0 was used for absence of the toxicity, and 1, 2, 3 and 4 were assigned for mild, moderate, severe, and very severe toxicities, respectively. The principal characteristic of grades 3 and 4 as opposed to grades 1 and 2 is interference with normal daily activity. Summary statistics of toxicities were evaluated a priori with regard to frequency distribution and cross-wise correlation. Overall survival and two toxicities with no indication of being strongly correlated (Spearman correlation coefficient=0.07) were picked for primary analysis: (1) sensoric neuropathy -grades seemed to be increasing with increasing number of cycles, and so time-to-event analysis was used, with time being the cycle number (0 to 9) and event time being the first cycle with reported increase in sensoric neuropathy score (CTC) of two from baseline, (2) neutrophil depression calculated as the difference between baseline and nadir divided by the baseline value in percent. Nadir was defined as the lowest observed value between two cycles regardless of the actual sampling time.
Seven other toxicities of which none seemed to be strongly cross-wise correlated (Spearman coefficient≤0.40) were left for explorative analysis: myalgia, arthralgia, mucositis, hearing loss, vomiting/nausea, motor neuropathy, and compliance. For all toxicities, the highest grade observed for any cycle was used. Nausea and vomiting seemed to be correlated (Spearman coefficient of 0.66), and the highest grade for either of the two was used. The grading for compliance was constructed using the actual dose of paclitaxel administered. Grade 1 was defined as at least one episode of reduced paclitaxel dose (range 50-90% of initial dose) and grade 2 as occurrence of at least one cycle where paclitaxel was not given. In two patients who experienced an allergic reaction during paclitaxel infusion only the subsequent cycles were evaluated for compliance. Evaluation of all toxicity data was completed and inserted in the database, which was locked, before the analyses of genetic variants were disclosed. Summary of the toxicities is presented in Table 2 .
Genotyping procedures
Genomic DNA was extracted from formalin-fixed, paraffinembedded tissue using QIAamp DNA Mini Kit, tissue protocol (VWR International A/S, Denmark) according to the manufacturer's protocol. SNPs in CYP2C8, CYP3A4, SLCO1B3 (except G767C), and ABCB1 (except A-1G) were determined using pyrosequencing as previously described [19] [20] [21] . The variants in CYP1B1, CYP3A5, ABCC1, and ABCC10; and G767C in SLCO1B3, A-1G in ABCB1, and rs2273697 in ABCC2 were genotyped using TaqMan® predesigned SNP genotyping assays by Applied Biosystems (Foster City, CA). SNPs in ABCG2 and rs17222723 and rs8187710 in ABCC2 were genotyped using SYBRgreen real-time PCR assays as previously described [22] .
Statistics
In order to overcome the problem of multiple testing, we split the analysis into a primary and an exploratory analysis. For the primary analysis, two-sided P-values with a significance level of 0.05 was used. [2] were tested one at a time in (Table 3 ). Age (≤65 or >65 years), CA125 levels at baseline (≤35 or >35 U/ml), and FIGO stage (trend from stage II to IV) were picked for the final model in which the SNPs were tested for trend. All calculations were carried out in STATA 10.
Results
Patients
One hundred and nineteen of 182 patients were eligible for analysis: 56 patients from the OVAR-9 trial and 63 from the TEC trial. Twenty and 31 patients were ineligible from the OVAR-9 and TEC trials, respectively, because of oncology departments not participating. Tissue was unavailable from a total of 12 patients from the participating departments. Characteristics are summarized in Table 1 .
Results of genotyping
Twenty-two single nucleotide polymorphisms (SNPs) were analyzed in 10 genes. For 57 patients both tumor and noncancerous tissue was available. The total call rate (across all SNPs) was 94.7%, evenly distributed (data not shown). Mismatching genotypes were found evenly distributed in 2.3% of the cases where both tumor and noncancerous tissue was available. In these cases no final genotype was called. In one patient all calls from the tumor sample were discarded because the DNA quality was obviously very poor with a call rate of 41% across the 22 SNPs. Allele frequencies were all similar to frequencies reported for Caucasians on the NCBI SNP database (dbSNP). The genotype distributions were all in Hardy-Weinberg equilibrium except CYP2C8*4, *1B and *1C, and ABCB1 A61G.
Toxicity
Toxicity registration was available from 710 treatment cycles (Table 2) . Twenty-three patients received treatment beyond the sixth cycle. One patient did not receive chemotherapy (no cause stated). Toxicity registration for this patient was not done, but survival data were included in the final analysis (intention to treat).
Primary analysis
No statistically significant correlations were found among the SNPs: CYP2C8*3, ABCB1 C1236T, G2677T/A, and C3435T and neutrophil depression and sensoric neuropathy (Table 4) . For overall survival, the calculated hazard ratio for the individual genotype as a covariate in the Cox model is reported along with the 95% confidence interval ( Table 4) . None of the SNPs selected for primary analysis were statistically significantly associated with overall survival of the patients. ABCB1 G2677T/A, which is a tri-allelic SNP, was tested excluding patients carrying an A allele. For completeness, analyses treating the A allele as a T allele and using the five genotypes as a categorical variable were also carried out.
Exploratory analysis
Among the 190 tests of association between particular toxicities and SNPs, 7 were found to have a P-value≤0.05 (data not shown). ABCB1 G1199A was associated with (Fig. 1) .
Discussion
Definite results linking frequent ABCB1 variants to taxane toxicity and effects in vivo have been elusive. This study retrospectively investigated possible correlations between a wide selection of candidate genes all with a reputed role in either the transport or the metabolism of paclitaxel and the toxicity and survival of patients treated with paclitaxel. Clinical data and formalin-fixed paraffin-embedded tissue were gathered from 119 patients with ovarian cancer who were treated with paclitaxel and carboplatin in either the OVAR-9 or the TEC trial. The genetic variant CYP2C8*3 (a paclitaxel-metabolizing enzyme) and three variants of the drug transporter ABCB1: C1236T, G2677T/A, and C3435T were picked a priori for primary analysis. No statistically significant correlation for sensoric neuropathy, neutrophil depression, and overall survival was found. This finding contrasts with the correlation reported by Nakajima et al. [23] for leukocytopenia and C3435T in 23 Japanese women with ovarian cancer and the report of Sissung et al. [24] who found a trend between neutrophil decrease and the ABCB1 C3435T/G2677T/A compound genotype in 26 patients with advanced solid tumors. Interestingly Gréen et al. [20] recently reported a correlation between CYP2C8*3 and hematological toxicity. We also conducted a wide exploratory analysis of 19 SNPs in a total of 10 genes and sensoric neuropathy, neutrophil depression, and overall survival and other toxicities that are related to paclitaxel treatment, i.e., myalgia, arthralgia, mucositis, hearing loss, motor neuropathy, vomiting/nausea, and compliance. This analysis encompasses some 190 tests (data not shown) of which 7 had a P-value≤0.05. This finding is likely due to chance alone, given the multiple testing. This multitude of statistical testing can serve a purpose for future investigations but has no value without being confirmed in other studies. None of the seven possible associations have to our knowledge been reported in the literature before. In the explorative analysis of overall survival, an association with the nonsynonymous G1199A SNP in the ABCB1 transporter was found with a P-value of 0.03 (uncorrected) and a hazard ratio of 2.03 (95% CI 1.08-3.83) favoring patients with 1199GG genotype (Fig. 1) . This is in accordance with the shorter progression-free survival for patients carrying the 1199GA genotype found by Gréen et al. [21] . Similarly Johnatty et al. [25] found a better progression-free survival for patients carrying the 2677TA alleles, and Gréen et al. [19] found an association for the same variant and good response to paclitaxel treatment. The finding should be confirmed in other studies before any conclusions can be made. CYP1B1*3 has previously been associated with survival after paclitaxel treatment in breast cancer [26, 27] , but this finding was not reproduced in our material of ovarian cancer.
In 2007 Marsh et al. [15] reported a very comprehensive retrospective pharmacogenetic study of toxicity and response to treatment with a taxane in 914 ovarian cancer patients. No significant association was found for a selection of variants in the candidate genes: ABCB1, ABCC1, ABCG2, CYP1B1, CYP2C8, and CYP3A4/5 and hematologic toxicity, neurotoxicity, and gastrointestinal toxicity. While this study included far more patients than our study and other previous studies, it also raised a debate concerning power and the interpretation of P-values [28] [29] [30] . Our results, however, do agree with the conclusions made by Marsh et al. but are again contrasted by a very recent paper by Leskelä et al. [31] , who demonstrated an association between CYP2C8*3 and CYP3A5 in a mixed retrospective/prospective study.
In this study, we investigate candidate genes with putative impact on the pharmacokinetics of paclitaxel under the assumption that these might influence toxicity or survival either directly through impact on clearance or the distribution of paclitaxel or indirectly through the paclitaxel concentration in the micro environment in the tumor and susceptible tissues (bone marrow, peripheral nerves, etc.). We have thus not addressed the possibility that the susceptibility of the mentioned targets by themselves is determined by genetic variation. Ideally, future pharmacogenetic studies of chemotherapy should try to combine the pharmacokinetic and the pharmacodynamic components. In conclusion, this study primarily investigated the notion that the genetic variants CYP2C8*3 and ABCB1 C1236T, G2677T/A, and C3435T explain some of the observed variability in toxicity and survival of ovarian cancer patients treated with paclitaxel and carboplatin. No statistically significant associations were found in the primary analysis. The study also involved an explorative analysis of other candidate genes that might be of value for studies in the future.
